ClinicalTrials.gg
CompletedNCT05142553Updated Nov 17, 2026

Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.

A Phase 2 interventional study of COVID-19 Vaccine HIPRA and Cominarty (Pfizer-BioNtech) in SARS-CoV 2 Infection, sponsored by Hipra Scientific, S.L.U. Completed at 10 sites in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hipra Scientific, S.L.U · Phase 2, Interventional, and Prevention

How we know

Updated Nov 17, 2026Start date movedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,164
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.

Enrollment
30th of 254
1,164 · median 132
Started
2021
with 106 others
Phase 2
54 of 401
1 open now
Registered
289th of 401
by date
Lead sponsor
7 of 401
Hipra Scientific, S.L.U

Among the 401 studies in COVID-19 with a site in Spain, this one is the 30th largest by enrollment of the 254 interventional ones that give a count, is one of 107 that started in 2021, is one of 54 in phase 2, and was the 289th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in COVID-19 with a site in Spain, or all of them as a file.
02

Study summary

This Phase IIb clinical study aims to compare the immunogenicity and safety of a booster dose of recombinant protein RBD fusion dimer vaccine as a heterologous booster (to subjects who have received the second dose of the Pfizer-BioNTech (Comirnaty) COVID-19 vaccine at least 182 days prior to the booster dose in this study) versus a homologous booster (subjects who received the second dose of the Comirnaty COVID-19 vaccine at least 182 days prior to the booster dose in this study) will receive a third dose of the Comirnaty vaccine).

The extension part of the study aims to compare the immunogenicity and safety of a fourth dose of PHH-1V in subjects with a primovaccination with Pfizer-BioNTech (Comirnaty) COVID-19 vaccine plus either a booster dose of Comirnaty or PHH-1V versus those with three vaccinations of Comirnaty.

Read the detailed description

The study population includes 1075 healthy adults aged above 18 years old who have received two doses of the Comirnaty vaccine, and are at least 182 days and less than 365 days after their second dose will be randomly assigned to two treatment arms. In each arm, volunteers will be randomized in a ratio Test vaccine:Comirnaty of 2:1. Each participant will receive one booster immunisation and will be followed for 1 year to evaluate immunogenicity response and assess the safety of the test vaccine in comparison to Cominarty.

The study population of the extension part includes 200 healthy adults abode 18 years old who have received or: 3 doses of Comirnaty vaccine, or 2 doses of Comirnaty + 1 dose of PHH-1V. Each participant will receive one dose of PHH-1V.

03

Conditions studied

  • SARS-CoV 2 Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Part A: Inclusion Criteria:

  • Male or female, by birth, ≥ 18 years old at Screening.
  • Willing and able to comply with scheduled visits, laboratory tests, complete diaries, and other study procedures.
  • (BMI) between 18 to 40 kg/m2.
  • Has received a complete COVID-19 vaccination programme (two administrations, prime and boosting) at least 182 days and with a maximum of 365 days before Screening with Comirnaty vaccine.
  • Has a negative COVID-19 polymerase chain reaction (PCR) test at Screening.
  • Willing to avoid all other vaccines within 4 weeks before and after vaccination in this study (Day 0). Seasonal influenza vaccination is allowed if it is received at least 14 days before or after vaccination.
  • Willing to refrain from blood donation during the study.
  • Women of must have a negative urine pregnancy test at Screening and prior to vaccination.
  • Women of childbearing potential must be willing to use highly effective methods or have practiced sexual abstinence from the screening visit until 8 weeks after the vaccination.
  • Males who are not sterilised, must be willing to avoid impregnating female partners from Screening until 8 weeks after vaccination.
  • Willing and able to provide written prior the initiation of any study procedures.

Part A: Exclusion criteria:

  • Pregnant or lactating or intending to become pregnant or plans to breastfeed during the study.
  • Positive pregnancy test at Screening or vaccination day.
  • Any medical disease (acute, subacute, intermittent, or chronic) or condition that in the opinion of the Investigator compromises the subject's safety, preclude vaccination or compromises interpretation of the results.
  • Ongoing serious psychiatric condition likely to affect participation in the study (e.g., ongoing severe depression, recent suicidal ideation, bipolar disorder, personality disorder, alcohol and drug dependency, severe eating disorder, psychosis, use of mood stabilisers or antipsychotic medication).
  • History of respiratory disease (e.g., [COPD]) requiring daily medications currently or any treatment of respiratory disease exacerbations (e.g., asthma exacerbation) in the last 6 months.
  • History of significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult. Controlled hypertension will be permitted at the discretion of the Investigator.
  • History of neurological or neurodevelopmental conditions (e.g., epilepsy, stroke, seizures in the last 3 years, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis, or transverse myelitis).
  • Ongoing or recent diagnosis of malignancy in the last five years excluding basal cell and squamous cell carcinoma of the skin, which are allowed.
  • Any confirmed or suspected , or immunodeficiency disease/condition (iatrogenic or congenital), including (HIV) infection, asplenia, or recurrent severe infections.
  • Acute illness within 72 hours before vaccination day that, in the opinion of the Investigator may interfere the evaluation of safety parameters.
  • Received drug within 90 days before Screening or plans to participate in another interventional clinical study (drug/biologic/device) within 12 months after vaccination.
  • History of or severe allergic reactions, including anaphylaxis, generalised urticarial, angioedema and other significant reactions related to food, drugs, vaccines, or pharmaceutical agents, which are likely to be exacerbated by any component of the COVID-19 vaccine HIPRA.
  • Use of any immunosuppressant, , or other immune-modifying drugs within 2 months before vaccination day; or anticipation of the need for immunosuppressive treatment within 182 days after vaccination.
  • Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days before vaccination (Day 0).
  • Known disturbance of coagulation (iatrogenic or congenital) or blood dyscrasias.
  • Known bleeding disorder (e.g., factor deficiency, coagulopathy, or disorder), (iatrogenic or congenital), blood dyscrasias, or prior history of significant bleeding or bruising following intramuscular (IM) injections or venepuncture.
  • Chronic liver disease.
  • Positive test for HIV types 1 or 2 infection, surface antigen (HBsAg), or virus antibodies (HCV Abs) at Screening.
  • Suspected or known current alcohol abuse or any other substances abuse (except tobacco).

History of COVID-19 infection.

  • Ever been included in a trial with an experimental vaccine against COVID-19.
  • Close contact with anyone known to have SARS-CoV-2 infection within 15 days before Screening.
  • Scheduled elective surgery during the study.
  • of less than 12 months.
  • Any condition and/or laboratory finding that, in the Investigators opinion, would interfere with the study or put the subject at risk.

Part B (fourth dose extension): Inclusion Criteria

  • Adults ≥ 18 years old at Day 0.
  • Participant must provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in this extension of the study and comply with all the study requirements and procedures.
  • Has received a primary vaccination of two doses of Comirnaty followed by a booster dose either with Comirnaty or PHH-1V. Last booster dose given between 6 and 12 months before Day 0.
  • Has a negative Rapid Antigen Test (RAT) at Day 0 before the fourth dose administration.
  • Participants may have underlying illnesses if are stable and well-controlled.
  • Participant is willing to avoid receiving (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine.
  • Participant agrees not to donate blood, blood products and bone marrow at least 12 weeks before and after vaccination
  • Contraceptive use for women of childbearing potential: hormonal, intrauterine device, vasectomized partner, sexual abstinence, condom.
  • Negative pregnancy test for WOCBP at Day 0.
  • Contraceptive use for males: vasectomized participants, condom, sexual abstinence.

Part B (fourth dose extension): Exclusion Criteria

  • History of anaphylactic shock of any kind
  • History of COVID-19 infection.
  • Pregnancy or breast-feeding at screening or Day 0
  • Participant has a acute illness or fever (temperature ≥38º C / 100.4ºF) at screening or within 48 hours prior to the planned vaccination
  • Participant had a surgery requiring hospitalization before vaccination and he/she has not received the hospital discharge at day 0
  • Participant has any active malignancy
  • Participant has ongoing severe and non-stable psychiatric condition likely to affect participation in the study
  • Participant has a problematic or risk use of substances including alcohol that can compromise the study follow-up
  • Participant has a bleeding disorder, blood dyscrasia, or continuous use of anticoagulants or has any condition that contraindicates intramuscular injections or frequent phlebotomy
  • Participant has abnormal function of the immune system as in autoimmune diseases, asplenia, recurrent infections or congenital/acquired immunodeficiency
  • Chronic or recurrent administration (during at least 14 days) of systemic immunosuppressant medication within 12 weeks preceding the planned administration of study vaccine
  • Subject has received immunoglobulins and/or blood-derived products 12 weeks prior vaccination
  • Participant received any immunotherapy (monoclonal antibodies, plasma) aimed to prevent or treat COVID-19 within 90 days preceding the planned administration of study vaccine
  • Participation in any research involving an investigational product (drug, biologic, device) within 12 weeks prior to vaccination and during the study
  • Participant has donated ≥ 450ml of blood products within 12 weeks before screening
  • Participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,164 participants (actual)

Study arms

  • Experimental
    COVID-19 Vaccine HIPRA

    40 ug/0.5 ml

    Biological: COVID-19 Vaccine HIPRA

  • Active comparator
    Cominarty (Pfizer-BioNtech)

    30 micrograms/dose concentrate for dispersion for injection

    Biological: Cominarty (Pfizer-BioNtech)

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Changes of the immunogenicity against Wuhan

    Neutralisation titre measured as inhibitory concentration 50 (IC50) for each individual sample and geometric mean titre (GMT) for treatment group comparison at Baseline and Day 14.

    Time frame: 14 days

  2. Safety and tolerability of PHH-1V as third or fourth dose

    Number, percentage, and characteristics of solicited local reactions through Day 7 after vaccination.

    Time frame: 7 days

  3. Safety and tolerability of PHH-1V as third or fourth dose

    Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through Day 28 after vaccination.

    Time frame: 28 days

  4. Safety and tolerability of PHH-1V as third or fourth dose

    Number and percentage of serious adverse events (SAEs), adverse event of special interest (AESI) and medically attended adverse events (MAAE) through Day 364.

    Time frame: 364 days

  5. Safety and tolerability of PHH-1V as third or fourth dose

    Change from baseline in safety laboratory parameters at Days 14, 28, 182, and 364 after vaccination.

    Time frame: Days 14, 28, 182, and 364

  6. Part B: Changes of the immunogenicity against Omicron BA.1

    Neutralisation titre measured as inhibitory concentration 50 (IC50) by PBNA and reported as log10 concentration for each individual sample and GMT, at Day 14 post-dose 4 of PHH-1V in cohort 2 versus post-dose 3 in cohort 2 (cohort 2 having three doses of Comirnaty + the frouth dose of PHH-1V).

    Time frame: Day 14

Secondary outcomes

  1. Changes of the immunogenicity against the Variants of Concern (VOC)

    Neutralisation titre against VOC measured as IC50 for each individual sample and GMT for treatment group comparison at Baseline and Days 28, 98, 182, and/or 364.

    Time frame: Day 14, 28, 98, 182, 364

  2. Changes of the immunogenicity against the Variants of Concern (VOC)

    Geometric mean fold rise (GMFR) in neutralising antibodies titres for treatment group comparison at Baseline and Days 14, 28, 98, 182, and/or 364.

    Time frame: Day 14, 28, 98, 182 and 364

  3. Changes of the immunogenicity against the Variants of Concern (VOC)

    Neutralisation titre against VOC measured as IC50 by PBNA and reported as reciprocal concentration for each individual sample and GMT for treatment group comparison at Baseline and Days 14, 28, 98, 182, and 364.

    Time frame: Day 14, 28, 98, 182 and 364

  4. Changes of the immunogenicity against the Variants of Concern (VOC)

    Geometric mean fold rise (GMFR) in neutralising antibodies titres for treatment group comparison at Baseline and Days 14, 28, 98, 182, and 364.

    Time frame: Day 14, 28, 98, 182 and 364

  5. Changes in immunogenicity at Baseline and Days 14, 28, 182 &364.

    Neutralisation titre measured as inhibitory dilution 50 (ID50) for each individual sample, and GMT for treatment group comparison at Baseline and Days 14, 28, 98, 182, and 364. This analysis will be performed in a subset of subjects.

    Time frame: Days 14, 28, 98, 182 and 364

  6. Immunogenicity to the SARS-CoV-2 spike glycoprotein

    Percentage of subjects that, after a booster dose, have a ≥4-fold change in binding antibodies titre from Baseline and Days 14, 28, 98, 182, and 364.

    Time frame: Days 14, 28, 98, 182, and 364

  7. T-cell mediated responses against the SARS-CoV-2 S glycoprotein at Baseline & D14.

    T-cell-mediated response to the SARS-CoV-2 S protein at Baseline and at Day 14. This analysis will be performed in a subset of subjects.

    Time frame: Day 14

  8. Th-1/Th-2 T-cell mediated responses against the SARS-CoV-2 S glycoprotein at Baseline & D14. Th-1/Th2

    CD4+/CD8+ T-cell response to the SARS-CoV-2 S protein at Baseline and at Day 14. This analysis will be performed in a subset of subjects.

    Time frame: Day 14

Other outcomes

  1. Number of subjects with SARS-CoV-2 infections in subjects without evidence of infection before study's participation.

    Number and percentage of subjects with SARS-CoV-2 infections according to COVID-19 infection criteria throughout the study duration.

    Time frame: 364 Days

  2. Number of COVID-19 severe infections after receiving PHH-1V.

    Number and percentage of COVID 19 severe infections through Day 364.

    Time frame: through Day 364.

  3. Number of COVID-19 severe infections after receiving PHH-1V.

    Number and percentage of hospital admissions associated with COVID 19 through Day 364.

    Time frame: through Day 364.

  4. Number of COVID-19 severe infections after receiving PHH-1V.

    Number and percentage of intensive care unit (ICU) admissions associated with COVID-19 through Day 364.

    Time frame: through Day 364.

  5. Number of COVID-19 severe infections after receiving PHH-1V.

    Number and percentage of deaths associated with COVID-19 through Day 364.

    Time frame: through Day 364.

07

Study locations

10 sites
  • Hospital Germans Trias I Pujol
    Badalona, BARCELONA 08916, Spain
  • Hospital Vall Hebron
    Barcelona, BARCELONA 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Barcelona 17170, Spain
  • Hospital Universitari Dr. Josep Trueta
    Girona, Girona 17007, Spain
  • Hospital Gregorio Marañón
    Madrid, Madrid 28007, Spain
  • Hospital Universitario La Paz
    Madrid, Madrid 28046, Spain
  • Hospital Principe de Asturias
    Meco, Madrid 28805, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, Málaga 29010, Spain
  • Hospital Clínico de Valencia
    Valencia, Valencia 46010, Spain
  • Hospital de Cruces
    Barakaldo, VIZCAYA 48903, Spain
08

References and documents

Publications

  • Corominas J, Garriga C, Prenafeta A, Moros A, Canete M, Barreiro A, Gonzalez-Gonzalez L, Madrenas L, Guell I, Clotet B, Izquierdo-Useros N, Raich-Regue D, Gallemi M, Blanco J, Pradenas E, Trinite B, G Prado J, Perez-Caballero R, Bernad L, Plana M, Esteban I, Aurrecoechea E, Taleb RA, McSkimming P, Soriano A, Nava J, Anagua JO, Ramos R, Marti Lluch R, Corpes Comes A, Otero Romero S, Martinez-Gomez X, Camacho-Arteaga L, Molto J, Benet S, Bailon L, Arribas JR, Borobia AM, Queiruga Parada J, Navarro-Perez J, Forner Giner MJ, Lucas RO, Vazquez Jimenez MDM, Lopez Fernandez MJ, Alvarez-Mon M, Troncoso D, Arana-Arri E, Meijide S, Imaz-Ayo N, Garcia PM, de la Villa S, Rodriguez Fernandez S, Prat T, Torroella E, Ferrer L. Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial. Vaccine. 2025 Feb 15;47:126685. doi: 10.1016/j.vaccine.2024.126685. Epub 2025 Jan 13. PubMed 39809095 ↗
  • Moros A, Prenafeta A, Barreiro A, Perozo E, Fernandez A, Canete M, Gonzalez L, Garriga C, Pradenas E, Marfil S, Blanco J, Cebollada Rica P, Sistere-Oro M, Meyerhans A, Prat Cabanas T, March R, Ferrer L. Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate. Vaccine. 2023 Aug 7;41(35):5072-5078. doi: 10.1016/j.vaccine.2023.07.008. Epub 2023 Jul 16. PubMed 37460353 ↗
  • Corominas J, Garriga C, Prenafeta A, Moros A, Canete M, Barreiro A, Gonzalez-Gonzalez L, Madrenas L, Guell I, Clotet B, Izquierdo-Useros N, Raich-Regue D, Gallemi M, Blanco J, Pradenas E, Trinite B, Prado JG, Blanch-Lombarte O, Perez-Caballero R, Plana M, Esteban I, Pastor-Quinones C, Nunez-Costa X, Taleb RA, McSkimming P, Soriano A, Nava J, Anagua JO, Ramos R, Lluch RM, Comes AC, Romero SO, Gomez XM, Sans-Pola C, Molto J, Benet S, Bailon L, Arribas JR, Borobia AM, Parada JQ, Navarro-Perez J, Forner Giner MJ, Lucas RO, Jimenez MDMV, Compan SO, Alvarez-Mon M, Troncoso D, Arana-Arri E, Meijide S, Imaz-Ayo N, Garcia PM, de la Villa Martinez S, Fernandez SR, Prat T, Torroella E, Ferrer L. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. Lancet Reg Health Eur. 2023 May;28:100613. doi: 10.1016/j.lanepe.2023.100613. Epub 2023 Apr 14. PubMed 37131861 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in May 2023, 18 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 18 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2021
First posted
Dec 2, 2021
StartActual
Nov 15, 2021
Primary completionActual
May 29, 2023
CompletionActual
May 29, 2023
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 16, 2021→Nov 15, 2021
Nov 17, 2026
Enrollment
887→1164
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date Nov 16, 2021→Nov 15, 2021
    Enrollment 887→1164
    + 6 other changes: identifiers, verification date, responsible party, conditions, design details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05142553
Lead sponsor
Hipra Scientific, S.L.U
Responsible party
Sponsor
First posted
Dec 2, 2021
Start date
Nov 15, 2021
Primary completion
May 29, 2023
Completion
May 29, 2023
Last update
Nov 17, 2026

Study contacts

Teresa Prat
study director · Hipra Scientific, S.L.U

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HIPRA COVID-19 vaccine

Start the discussion